Zimmer Biomet Holdings (ZBH) Announces Statistical Superiority in Seven-Year Follow-up of Mobi-C vs. Two-Level ACDF
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures extend losses after economic data
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Zimmer Biomet Announces Positive Comparative Data from 7-Year Follow-Up Study of Mobi-C® Cervical Disc Prosthesis for Cervical Disc Replacement
October 26, 2016 5:07 PM EDTWARSAW, Ind., Oct. 26, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced results of a seven-year outcomes study demonstrating statistical superiority of its Mobi-C® Cervical Disc Prosthesis versus two-level anterior cervical discectomy and fusion (ACDF) in overall success. In the study, overall success required improvement in Neck Disability Index (NDI), no secondary surgical interventions at the index levels, and absence of major complications defined as radiographic failure, neurological failure or adverse events. Mobi-C was the first cervical disc prosthesis approved by... More
